131 related articles for article (PubMed ID: 26147581)
1. Development of Radiolabeled Membrane Type-1 Matrix Metalloproteinase Activatable Cell Penetrating Peptide Imaging Probes.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
Molecules; 2015 Jul; 20(7):12076-92. PubMed ID: 26147581
[TBL] [Abstract][Full Text] [Related]
2. Imaging of MMP activity in postischemic cardiac remodeling using radiolabeled MMP-2/9 activatable peptide probes.
van Duijnhoven SM; Robillard MS; Hermann S; Kuhlmann MT; Schäfers M; Nicolay K; Grüll H
Mol Pharm; 2014 May; 11(5):1415-23. PubMed ID: 24641497
[TBL] [Abstract][Full Text] [Related]
3. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
J Nucl Med; 2011 Feb; 52(2):279-86. PubMed ID: 21233187
[TBL] [Abstract][Full Text] [Related]
4. In vivo biodistribution of radiolabeled MMP-2/9 activatable cell-penetrating peptide probes in tumor-bearing mice.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
Contrast Media Mol Imaging; 2015; 10(1):59-66. PubMed ID: 24823643
[TBL] [Abstract][Full Text] [Related]
5. Radioiodinated Peptidic Imaging Probes for in Vivo Detection of Membrane Type-1 Matrix Metalloproteinase in Cancers.
Kondo N; Temma T; Shimizu Y; Ono M; Saji H
Biol Pharm Bull; 2015; 38(9):1375-82. PubMed ID: 26328493
[TBL] [Abstract][Full Text] [Related]
6. Development of PEGylated peptide probes conjugated with (18)F-labeled BODIPY for PET/optical imaging of MT1-MMP activity.
Kondo N; Temma T; Deguchi J; Sano K; Ono M; Saji H
J Control Release; 2015 Dec; 220(Pt A):476-483. PubMed ID: 26578437
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide.
Du Y; Lin X; Feng Q; Pan X; Song S; Yang J
Anticancer Drugs; 2022 Jan; 33(1):e562-e572. PubMed ID: 34338241
[TBL] [Abstract][Full Text] [Related]
8. In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.
Shimizu Y; Temma T; Hara I; Makino A; Kondo N; Ozeki E; Ono M; Saji H
Cancer Sci; 2014 Aug; 105(8):1056-62. PubMed ID: 24863849
[TBL] [Abstract][Full Text] [Related]
9. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage.
Shi NQ; Gao W; Xiang B; Qi XR
Int J Nanomedicine; 2012; 7():1613-21. PubMed ID: 22619516
[TBL] [Abstract][Full Text] [Related]
10. MT1-MMP activatable fluorogenic probes with enhanced specificity via high-affinity peptide conjugation for tumor imaging.
Ji X; Xie S; Jiao Y; Zhang X; Sun D; Yang VC; Wang M; He H; Sun L
Biomater Sci; 2020 Apr; 8(8):2308-2317. PubMed ID: 32186291
[TBL] [Abstract][Full Text] [Related]
11. Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection.
Shimizu Y; Temma T; Sano K; Ono M; Saji H
Cancer Sci; 2011 Oct; 102(10):1897-903. PubMed ID: 21718387
[TBL] [Abstract][Full Text] [Related]
12. Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers.
Kondo N; Temma T; Shimizu Y; Watanabe H; Higano K; Takagi Y; Ono M; Saji H
Cancer Sci; 2013 Apr; 104(4):495-501. PubMed ID: 23305265
[TBL] [Abstract][Full Text] [Related]
13. [The design and enzymatic hydrolysis of activatable cell-penetrating peptide].
Wang PC; Qi XR
Yao Xue Xue Bao; 2010 Aug; 45(8):1048-51. PubMed ID: 21351594
[TBL] [Abstract][Full Text] [Related]
14. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery.
Crisp JL; Savariar EN; Glasgow HL; Ellies LG; Whitney MA; Tsien RY
Mol Cancer Ther; 2014 Jun; 13(6):1514-25. PubMed ID: 24737028
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method.
Sano K; Temma T; Kuge Y; Kudo T; Kamihashi J; Zhao S; Saji H
Biol Pharm Bull; 2010; 33(9):1589-95. PubMed ID: 20823579
[TBL] [Abstract][Full Text] [Related]
17. Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.
Remacle AG; Cieplak P; Nam DH; Shiryaev SA; Ge X; Strongin AY
Oncotarget; 2017 Jan; 8(2):2781-2799. PubMed ID: 27835863
[TBL] [Abstract][Full Text] [Related]
18. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2.
Nishida Y; Miyamori H; Thompson EW; Takino T; Endo Y; Sato H
Cancer Res; 2008 Nov; 68(21):9096-104. PubMed ID: 18974156
[TBL] [Abstract][Full Text] [Related]
19. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
[TBL] [Abstract][Full Text] [Related]
20. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors.
Temma T; Sano K; Kuge Y; Kamihashi J; Takai N; Ogawa Y; Saji H
Biol Pharm Bull; 2009 Jul; 32(7):1272-7. PubMed ID: 19571397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
